References
- Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Vdovic S, Schmeiser HH, Cosyns JP. (2002a) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101: 500-502.
- Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Stiborova M. (2006) Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett 234: 220-231.
- Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singhs R, da Costa GG, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH. (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29: 656-665.
- Arlt VM, Stiborova M, Schmeiser HH. (2002b) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17: 265-277.
- Arlt VM, Alunni-Perret M, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns J-P. (2004) Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 111: 977-980.
- Arlt VM, Stiborová M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. (2007) Aristolochic acid mutagenesis: molecular clues to the etiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogensis 28: 2253-2261.
- Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65: 2644-2652.
- Chan W, Cu L, Xu G, Cai Z. (2006) Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom 20: 1755-1760.
- Chan W, Luo H-B, Zheng Y, Cheng Y-K, Cai Z. (2007) Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats, Drug Metab Dispos 35: 866-874.
- Cosyns JP. (2003) Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Safety 26: 33-48.
- Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutan S. (2006) Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 34: 1122-1127.
- Gillerot G, Jadoul M, Arlt VM, van Ypersele de Strihou C, Schmeiser HH, But PHH, Bieler CA, Cosyns J-P. (2001) Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"? Am J Kidney Dis 38: E26.
- Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky R, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy, Proc Natl Acad Sc USA, 104: 12129-12134.
- Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. (2005) Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J, 46: 116-125.
- IARC (International Agency for Research on Cancer). (2002) Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 82.
- Ivic M. (1969) Etiology of endemic nephropathy. Lijec Vjesn 91: 1273-1281.
- Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. (2004) Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Nat Acad Sc USA 101: 2963-2968.
- Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. (2004) DNA adducts and p53 mutations in a patient with aristolochic acidassociated nephropathy. Am J Kidney Dis 43: e11-17.
- Meinl W, Pabel U, Osterloh-Quitroz H, Hengstler JG, Glatt H. (2006) Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 118: 1090-1097.
- Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petřin M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686-1692.
- Nortier JL, Schmeiser HH, Martinez MCM, Arlt VM, Vervaet C, Garbar CH, Daelemans P, Vanherweghem JL. (2003) Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant 18: 426-428.
- Qi X, Cai Y, Gong L, Liu L, Chen F, Xiao Y, Wu X, Li Y, Xue X, Ren J. (2007) Role of mitochondrial permeability transition in human renal tubuar epithelial cell death induced by aristolochic acid. Toxicol Appl Pharmacol 222: 105-110.
- Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56: 2025-2028.
- Stefanovic V, Toncheva D, Atanasova S, Polenakovic M. (2006) Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am J Nephrol 26: 1-11.
- Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH, Frei E. (2008a) Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-327.
- Stiborová M, Frei E, Arlt VM, Schmeiser HH. (2008b) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658: 55-67.
- Stiborová M, Frei E, Breuer A, Bieler C A, Schmeiser HH. (1999) Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp Toxic Pathol 51: 421-427.
- Stiborová M, Frei E, Breuer A, Wiessler M, Schmeiser HH. (2001a) Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase - 32P-postlabeling analysis of DNA adduct formation. Mutat Res 493: 149-160.
- Stiborová M, Frei E, Wiessler M, Schmeiser HH. (2001c) Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochrome P450 1A1 and 1A2. Chem Res Toxicol 14: 1128-1137.
- Stiborová M, Frei E, Schmeiser HH. (2008c) Biotransformation enzymes in development of renal injury and urothelial cancer cause by aristolochic acid. Kidney Int 73: 1209-1211.
- Stiborová M, Frei E, Sopko B, Wiessler M, Schmeiser HH. (2002a) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23: 617-625.
- Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Laňková M, Kumstýřová T, Wiessler M, Schmeiser HH. (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24: 1695-1703.
- Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH. (2005a) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113: 189-197.
- Stiborová M, Hájek M, Frei E, Schmeiser HH. (2001b) Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys 20: 375-392.
- Stiborová M, Patočka J, Frei E, Schmeiser HH. (2005b) Biochemistry and toxicological aspects of etiology of Balkan endemic nephropathy [in Czech]. Chem Listy 99: 782-788.
- Stiborová M, Sopko B, Hodek P, Frei E, Schmeiser HH, Hudeček J. (2005c) The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett 229: 193-204.
- Tatu CA, Oren WH, Finkelman RB, Feder GL. (1998) The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect 106: 689-700.
- Toncheva DI, von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VM, Oellerich M. (2004) Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 17: 384-389.
- Toncheva D. (2006) Genetic studies in BEN and associated urothelial cancers. Coll. Antropol 30(Suppl 1): 34.
- Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Valdervelde D, Verbeelen D, Vanhaelen-Fastre B, Vanhaelen M. (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391.
- Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. (1994) Identification of aristolochic acid in Chinese herbs. Lancet 343: 174.
- Xiao Y, Ge M, Xue X, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, Li Y, Xie T, Gu J, Ren J. (2008) Detoxication role of hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int 73: 1231-1239.